Initial management of high risk early stage prostate cancer: Radiation

Eric M. Horwitz, Steven J. Feigenberg, Alan Pollack

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Introduction Because there are many treatment options for nonmetastatic prostate cancer, it is vitally important to define risk and determine a patient’s prognosis to aid in the treatment design. Risk is defined many ways, although the single most important prognostic variable is a person’s pretreatment PSA level.1 Other important variables include Gleason score, T stage, and radiation dose.2 At Fox Chase Cancer Center (FCCC) and elsewhere, these variables are used to categorize men into multiple risk groups.3-5 Patients with low-risk disease include those with PSA (10 ng/mL, Gleason score 2 to 6 and T1c/T2a disease. The high-risk group consists of patients having one of the following high-risk features: Gleason score 8 to 10, PSA greater than 20 ng/mL, or T3/T4 disease. Intermediate-risk patients do not fit into either of the above risk groups. Treatment options for low-and high-risk disease are discussed elsewhere. The focus of this chapter is on radiation treatment options for men with intermediate risk prostate cancer.

Original languageEnglish (US)
Title of host publicationTreatment Methods for Early and Advanced Prostate Cancer
PublisherCRC Press
Pages205-211
Number of pages7
ISBN (Electronic)9780203091432
ISBN (Print)0415458935, 9780415458931
StatePublished - Jan 1 2008
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Initial management of high risk early stage prostate cancer: Radiation'. Together they form a unique fingerprint.

  • Cite this

    Horwitz, E. M., Feigenberg, S. J., & Pollack, A. (2008). Initial management of high risk early stage prostate cancer: Radiation. In Treatment Methods for Early and Advanced Prostate Cancer (pp. 205-211). CRC Press.